Journal of International Oncology ›› 2018, Vol. 45 ›› Issue (6): 358-361.doi: 10.3760/cma.j.issn.1673-422X.2018.06.009
Previous Articles Next Articles
Bai Rilan, Guo Hanfei, Cui Jiuwei
Received:
2017-12-29
Online:
2018-06-08
Published:
2018-07-31
Contact:
Cui Jiuwei
E-mail:cuijw@jlu.edu.cn
Bai Rilan, Guo Hanfei, Cui Jiuwei. Evaluation criteria for tumor efficacy in the times of immunotherapy[J]. Journal of International Oncology, 2018, 45(6): 358-361.
[1] Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated nonsmallcell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265. DOI: 10.1016/S0140-6736(16)32517-X. [2] Rosenberg JE, HoffmanCensits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinumbased chemotherapy: a singlearm, multicentre, phase 2 trial[J]. Lancet, 2016, 387(10031): 1909-1920. DOI: 10.1016/S0140-6736(16)00561-4. [3] Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as firstline therapy for patients with PDL1positive advanced nonsmall cell lung cancer: a phase 1 trial[J]. Ann Oncol, 2017, 28(4): 874-881. DOI: 10.1093/annonc/mdx008. [4] Carlino MS, Long GV. Ipilimumab combined with nivolumab: a standard of care for the treatment of advanced melanoma?[J]. Clin Cancer Res, 2016, 22(16): 3992-3998. DOI: 10.1158/10780432.CCR-15-2944. [5] Chiou VL, Burotto M. Pseudoprogression and immunerelated response in solid tumors[J]. J Clin Oncol, 2015, 33(31): 3541-3543. DOI: 10.1200/JCO.2015.61.6870. [6] Tarhini AA. Tremelimumab: a review of development to date in solid tumors[J]. Immunotherapy, 2013, 5(3): 215-229. DOI: 10.2217/imt.13.9. [7] Wolchok JD, Hoos A, O′day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria[J]. Clin Cancer Res, 2009, 15(23): 7412-7420. DOI: 10.1158/1078-0432.CCR-09-1624. [8] Nishino M, Gargano M, Suda M, et al. Optimizing immunerelated tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?[J]. J Immunoth Cancer, 2014, 2: 17. DOI: 10.1186/2051-1426-2-17. [9] Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017, 18(3): E143-152. DOI: 10.1016/S1470-2045(17)30074-8. [10] Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer, 1981, 47(1): 207-214. [11] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3): 205216. [12] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026. [13] Fabel M, Wulff A, Heckel F, et al. Clinical lymph node staginginfluence of slice thickness and reconstruction kernel on volumetry and RECIST measurements[J]. Eur J Radiol, 2012, 81(11): 3124-3130. DOI: 10.1016/j.ejrad.2012.03.008. [14] Kwak JJ, Tirumani SH, Van den Abbeele AD, et al. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immunerelated adverse events[J]. Radiographics, 2015, 35(2): 424-437. DOI: 10.1148/rg.352140121. [15] Weiss J, Notohamiprodjo M, Bedke J, et al. Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma[J]. Curr Opin Urol, 2018, 28(1): 3541. DOI: 10.1097/MOU.0000000000000463. [16] Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an antiPD1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmallcell lung cancer (CheckMate 063): a phase 2, singlearm trial[J]. Lancet Oncol, 2015, 16(3): 257-265. DOI: 10.1016/S1470-2045(15)70054-9. [17] Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immunerelated response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab[J] . J Clin Oncol, 2016, 34(13): 1510-1517. DOI: 10.1200/JCO.2015.64.0391. [18] Carter CA, Schmitz B, Peterson PG, et al. Immune reactivity and pseudoprogression or tumor flare in a serially biopsied neuroendocrine patient treated with the epigenetic agent RRx001[J]. Case Rep Oncol, 2016, 9(1): 164-170. DOI: 10.1159/000444633. [19] Cohen JV, Alomari AK, Vortmeyer AO, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment[J]. Cancer Immunol Res, 2016, 4(3): 179-182. DOI: 10.1158/2326-6066.CIR-15-0160. [20] Bayo Calero J, Avió Tarazona V. A rapid response to pembrolizumab in a patient with metastatic melanoma[J]. Immunotherapy, 2017, 9(3): 225-228. DOI: 10.2217/imt-2016-0136. [21] Iijima Y, Hirotsu Y, Amemiya K, et al. Very early response of circulating tumourderived DNA in plasma predicts efficacy of nivolumab treatment in patients with nonsmall cell lung cancer[J]. Eur J Cancer, 2017, 86: 349357. DOI: 10.1016/j.ejca.2017.09.004. [22] Sanmamed MF, PerezGracia JL, Schalper KA, et al. Changes in serum interleukin8 (IL8) levels reflect and predict response to antiPD-1 treatment in melanoma and nonsmallcell lung cancer patients[J]. Ann Oncol, 2017, 28(8): 1988-1995. DOI: 10.1093/annonc/mdx190. [23] Nishino M, GiobbieHurder A, Manos MP, et al. Immunerelated tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions[J]. Clin Cancer Res, 2017, 23(16): 4671-4679. DOI: 10.1158/1078-0432.CCR-17-0114. [24] Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD1 or PDL1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria[J]. Eur J Cancer, 2018, 88: 38-47. DOI: 10.1016/j.ejca.2017.10.017. [25] Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by antiPD1/PDL1[J]. Clin Cancer Res, 2017, 23(8): 1920-1928. DOI: 10.1158/1078-0432.CCR-16-1741. [26] Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancerspecific and therapyspecific response criteria to complement pitfalls of RECIST[J]. AJR Am J Roentgenol, 2012, 198(4): 737-745. DOI: 10.2214/AJR.11.7483. [27] Nishino M, GiobbieHurder A, Gargano M, et al. Developing a common language for tumor response to immunotherapy: immunerelated response criteria using unidimensional measurements[J]. Clin Cancer Res, 2013, 19(14): 3936-3943. DOI: 10.1158/10780432.CCR-13-0895. [28] Reck M, RodriguezAbreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PDL1positive nonsmallcell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833. DOI: 10.1056/NEJMoa1606774. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353. |
[6] | Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[10] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[11] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[12] | Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[13] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[14] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[15] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||